Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Anorexia 6Cachexia 5Weight Loss 3Breast Neoplasms 3Neoplasms 2Lung Neoplasms 2Body Weight 2Squamous Cell Carcinoma of Head and Neck 1Prosthesis Failure 1Pancreatic Neoplasms 1Nutrition Disorders 1Menorrhagia 1Liver Neoplasms 1Leiomyoma 1Hot Flashes 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Body Weight Changes 1

Interventions

relugolix 8ulipristal acetate 7telapristone acetate 7estradiol, norethindrone drug combination 7vilaprisan 6asoprisnil 6Estradiol 5linzagolix 4elagolix 4Norethindrone Acetate 3Leuprolide 3Sugars 2Progestins 2epigallocatechin gallate 1Uterine Myomectomy 1Uterine Artery Embolization 1Tranexamic Acid 1Tea 1Standard of Care 1Sodium Chloride 1Saline Solution 1Misoprostol 1Mifepristone 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Laparoscopy 1Iron 1Hysterectomy 1Goserelin 1Gonadotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leiomyoma × Megestrol Acetate × Clear all
NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡